Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status
JAMA Surgery · 01.03.2024 · 159 (3) · 260
DOI: 10.1001/jamasurg.2023.6904 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.03.2024. Verfasst von Roger Olofsson Bagge und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Sentinel Lymph Node, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Patients with melanoma are selected for sentinel lymph node biopsy (SLNB) based on their risk of a positive SLN. To improve selection, the Memorial Sloan Kettering Cancer Center (MSKCC) and Melanoma Institute Australia (MIA) developed predictive models, but the utility of these models remains to be tested.
Objective
To determine the clinical utility of the MIA and MSKCC models. Design, Setting, and Participants This was a population-based comparative effectiveness research study including 10 089 consecutive patients with cutaneous melanoma undergoing SLNB from the Swedish Melanoma Registry from January 2007 to December 2021. Data were analyzed from May to August 2023. Main Outcomes and Measures, The predicted probability of SLN positivity was calculated using the MSKCC model and a limited MIA model (using mitotic rate as absent/present instead of count/mm 2 and excluding the optional variable lymphovascular invasion) for each patient. The operating characteristics of the models were assessed and compared. The clinical utility of each model was assessed using decision curve analysis and compared with a strategy of performing SLNB on all patients.
Results
Among 10 089 included patients, the median (IQR) age was 64.0 (52.0-73.0) years, and 5340 (52.9%) were male. The median Breslow thickness was 1.8 mm, and 1802 patients (17.9%) had a positive SLN. Both models were well calibrated across the full range of predicted probabilities and had similar external area under the receiver operating characteristic curves (AUC; MSKCC: 70.8%; 95% CI, 69.5-72.1 and limited MIA: 69.7%; 95% CI, 68.4-71.1). At a risk threshold of 5%, decision curve analysis indicated no added net benefit for either model compared to performing SLNB for all patients. At risk thresholds of 10% or higher, both models added net benefit compared to SLNB for all patients. The greatest benefit was observed in patients with T2 melanomas using a threshold of 10%; in that setting, the use of the nomograms led to a net reduction of 8 avoidable SLNBs per 100 patients for the MSKCC nomogram and 7 per 100 patients for the limited MIA nomogram compared to a strategy of SLNB for all. Conclusions and Relevance This study confirmed the statistical performance of both the MSKCC and limited MIA models in a large, nationally representative data set. However, decision curve analysis demonstrated that using the models only improved selection for SLNB compared to biopsy in all patients when a risk threshold of at least 7% was used, with the greatest benefit seen for T2 melanomas at a threshold of 10%. Care should be taken when using these nomograms to guide selection for SLNB at the lowest thresholds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
- Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
- Dermatology, Skagit Regional Health, Mt Vernon, Washington.
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Förderung
- NCI NIH HHS
Zitieren
APA
Olofsson Bagge, R., Mikiver, R., Marchetti, M. A., Lo, S. N., van Akkooi, A. C. J., Coit, D. G., Ingvar, C., Isaksson, K., Scolyer, R. A., Thompson, J. F., Varey, A. H. R., Wong, S. L., Lyth, J., & Bartlett, E. K. (2024). Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surgery, 159(3), 260. https://doi.org/10.1001/jamasurg.2023.6904
Vancouver
Olofsson Bagge R, Mikiver R, Marchetti MA, Lo SN, van Akkooi ACJ, Coit DG, et al. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surgery. 2024;159(3):260. doi:10.1001/jamasurg.2023.6904
BibTeX
@article{OlofssonBagge2024,
author = {Olofsson Bagge, Roger and Mikiver, Rasmus and Marchetti, Michael A and Lo, Serigne N and van Akkooi, Alexander C J and Coit, Daniel G and Ingvar, Christian and Isaksson, Karolin and Scolyer, Richard A and Thompson, John F and Varey, Alexander H R and Wong, Sandra L and Lyth, Johan and Bartlett, Edmund K},
title = {Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status},
journal = {JAMA Surgery},
year = {2024},
volume = {159},
number = {3},
pages = {260},
doi = {10.1001/jamasurg.2023.6904}
}
EUVIMED